ATR–CHK1 inhibition may prime tumors for immune attack by increasing tumor neoantigen burden, promoting MHC-I expression, and enhancing CD8+ T-cell infiltration, especially when combined with radiotherapy or immune checkpoint inhibitors. Here, CD8A is linked to neoplasm.